Articles tagged "Immunosuppression"

2018 American Transplant Congress
Designing Novel Selective Immunoproteasome Inhibitors Reveals a Critical Role of the Immunoproteasome in Protecting Antibody Secreting B Cells from Apoptosis
J. Assaker,¹ N. Murakami,¹ S. Eskandari,¹ M. Uehara,¹ C. Nathan,² H. Li,³ G. Lin,² J. Azzi.¹
¹Transplantation Renal Center, Harvard Medical School, Boston; ²Microbiology and Immunology, Weill Cornell Medicine, New York; ³Cryo-EM Structural Biology Laboratory, Van Andel Research Institute, Grand Rapids.
Constitutive proteasomes (c-20S) are ubiquitously-expressed cellular proteases that degrade polyubiquitinated proteins and regulate cell functions. Its inhibitor, bortezomib, is a plasma cell-targeted therapy used in…
2018 American Transplant Congress
Tissue Talks: Graft´s Histological Findings 10 Years after Belatacept or CNI
G. Mondragon-Ramirez,¹ N. Uribe-Uribe,² J. Arreola-Guerra,⁵ R. Reyes-Acevedo,⁵ M. Vilatoba,³ J. Furuzawa-Carballeda,⁴ A. Lopez-Toledo,¹ G. Mondragon-Salgado,¹ J. Alberu.³
¹Inst Mex de Trasplantes, Cuernavaca, Mexico; ²Pathology, Inst Nal de C. Médicas y Nutrición SZ, Mexico City, Mexico; ³Transplantation, Inst Nal de C. Médicas y Nutrición SZ, Mexico City, Mexico; ⁴Immunology, Inst Nal de C. Médicas y Nutrición SZ, Mexico City, Mexico; ⁵Transplantation, C Hospital Miguel Hidalgo, Aguascalientes, Mexico.
The BENEFIT study demonstrated that 7 yrs after kidney transplantation (KT), mean eGFR, patient and graft survival, were significantly higher in the belatacept group than…
2018 American Transplant Congress
Transplantation Tolerance Prevents CMV Reactivation and Preserves Kidney Allograft Function in a D+/R- Transplant Setting
A. Dangi,¹ J-.J. Wang,² M. Burnette,¹ Z. Zhang,² X. Luo.^1,2
¹Division of Nephrology and Hypertension, Department of Medicine, Northwestern University, Chicago, IL; ²Comprehensive Transplant Center, Department of Surgery, Northwestern University, Chicago, IL.
Background: Immune responses to cytomegalovirus (CMV) infection may precipitate acute/chronic graft rejection in immunocompromised transplant recipients. CMV infection can be primary or its reactivation from…
2018 American Transplant Congress
Patients Converted to Belatacept Show Different Immunophenotyping Compared with De Novo Belatacept-Treated Patients
M. Rial,¹ F. Caro,² A. Nella,² D. Guerrieri,² L. León,¹ P. Uva,¹ E. Chuluyan,² D. Casadei.¹
¹Instituto de Nefrología, Nephrology, Buenos Aires, Argentina; ²CEFYBO, UBA, CONICET, Buenos Aires, Argentina.
The incidence of adverse clinical events mainly in early, but not late post-transplantation such as an increased rate of acute rejection precludes the use of…
2018 American Transplant Congress
Effect of Everolimus on Body Composition; 1-Year after Kidney Transplantation
M. Yoshikawa,¹ T. Ishimura,² S. Nishi.¹
¹Division of Nephrology, Kobe University Graduate School of Medicine, Kobe, Japan; ²Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
【Background】Weight gain, and especially visceral fat gain early after kidney transplantation has a worse outcome for metabolic disorder, graft function, and cardiovascular disease. The mammalian…
2018 American Transplant Congress
Human CD8⁺CD28^– T Cells Driven In Vitro by IL-15 Suppress in Allo-Specific Manner Partially through PD-1:PD-L1 Pathway
F. Feng,^1,2 G. Liu,¹ P. Zhu,¹ M. Zhu,¹ X. Lu,¹ J. Liu,² X. Luo,³ Y. Liu,¹ Y. Yu.²
¹Department of Immunology, School of Basic Medical Science, Southern Medical University, Guangzhou, Guangdong, China; ²Department of Urology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China; ³Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.
Background: CD8+CD28- T suppressor cells (Ts) have emerged as an important modulator of alloimmunity, but the in vitro inducibility of Ts subsets is rather unclear.…
2018 American Transplant Congress
Once-Daily versus Twice-Daily Tacrolimus in De Novo Living Kidney Transplantation Patients: A Multicenter, Parallel Group, Open-Label, 5-Year Randomized Noninferiority Trial
Y. Kakuta,¹ M. Okumi,¹ K. Unagami,² M. Furusawa,¹ H. Ishida,¹ K. Tanabe.¹
¹Urology, Tokyo Women's Medical University, Tokyo, Japan; ²Nephrology, Tokyo Women's Medical University, Tokyo, Japan.
BackgroundTacrolimus is available as twice-daily (TAC-BID) and once-daily (TAC-QD) formulations. Findings from pharmacokinetic and short-term trials are available. However, results from long-term trials are limited.We…
2018 American Transplant Congress
Maintenance Immunosuppression Trends in Hand and Facial VCA Transplantation
A. Manjunath,¹ M. Cammarata,¹ R. Kantar,¹ W. Rifkin,¹ A. Jacoby,¹ B. Gelb,² R. Diaz-Siso,¹ E. Rodriguez.¹
¹Hansjörg Wyss Department of Plastic Surgery, NYU Langone Health, New York, NY; ²Transplant Institute, NYU Langone Health, New York, NY.
PURPOSE: Authors have speculated that vascularized composite allotransplantation recipients (VCAR) require greater maintenance immunosuppression than solid organ recipients due to skin's higher antigenicity. This has…
2018 American Transplant Congress
Influence of Trough Level in Tacrolimus on the Appearance Rate of De Novo Donor Specific Antibody (dnDSA) under Low Dose-Based Tacrolimus Protocol during 7 Years Follow-Up after Renal Transplantation
H. Ishida,¹ K. Tanabe,² T. Shimizu,¹ M. Furusawa.²
¹Organ Transplantation Medicine, Tokyo Women's Medical University, Tokyo, Japan; ²Urology, Tokyo Women's Medical University, Tokyo, Japan.
Background. Tacrolimus low trough protocol has been adopted at our institution since 2000.The purpose in this study is to investigate the relationship between maintenance trough…
2018 American Transplant Congress
Transplant Cost Reduction in a Developing Country: “The Case of Guatemala”
S. Méndez,¹ B. Remey,² E. Reyes,¹ A. Aguilar-González,¹ R. Lou-Meda.¹
¹Servicio de Nefrología, Hipertensión, Diálisis y Trasplante Hospital Roosevelt/FUNDANIER, Guatemala, Guatemala; ²Department of Pharmaceutical Chemistry, Universidad del Valle de Guatemala, Guatemala, Guatemala.
Background: Guatemala, south-west of Mexico has a population of approximately 16 million people of which 60% are younger than 20 years. As any other developing…